Harrow has unveiled three additional studies for its retinal drug portfolio during the 2026 American Society of Retina Specialists (ASRS) Annual Meeting, offering clinicians, investors and local observers new data on both safety and patient experience.
Key data disclosed at ASRS
The presentations included an interim randomised dataset for IHEEZO, a near‑20,000‑injection safety analysis related to that product and interim post‑marketing results for BYOOVIZ supplied by Samsung Bioepis. Collectively these disclosures broaden the clinical evidence for Harrow’s retina franchise and add scale to its safety profile.
- IHEEZO — interim randomised data signalling an improved post‑injection patient experience;
- Safety analysis — evaluation covering almost 20,000 injections associated with IHEEZO;
- BYOOVIZ — interim real‑world, post‑marketing findings contributed by Samsung Bioepis.
What this means for Harrow’s commercial story
The new material strengthens the clinical foundation under Harrow’s retina offerings, reinforcing safety and tolerability elements that are important to clinicians and patients. However, the company’s broader investment case still hinges on execution: translating clinical evidence into wider uptake and sustained revenue growth.
Harrow’s strategy relies on converting adoption of key products into financial returns while managing pricing and launch risk. The ASRS disclosures support product credentials but do not, by themselves, remove the reliance on upcoming pivotal readouts and commercial performance to meet market expectations.
Near‑term milestones and risks
Alongside the ASRS material, Harrow has progressed other clinical programmes. The company’s nearer‑term trajectory will be shaped by sales execution in 2026 and the outcome of pivotal trials such as the QUELL study referenced by company communications. Should launches fall short of expectations or pricing prove a barrier, Harrow’s concentration on a small number of flagship brands could amplify downside risk.
| Metric | Figure |
|---|---|
| Safety injections analysed | ~20,000 |
| Projected 2029 revenue (company narrative) | $784.8m |
| Projected 2029 earnings (company narrative) | $246.0m |
For residents following local companies, the ASRS disclosures are a reminder that clinical evidence and commercial delivery must advance together for a healthcare company to realise its projections. Investors and clinicians will be watching subsequent pivotal data and market uptake closely.
